enGene Holdings Inc. (ENGNW)
| Market Cap | 479.64M +61.1% |
| Revenue (ttm) | n/a |
| Net Income | -122.44M |
| EPS | -2.22 |
| Shares Out | 66.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,123 |
| Open | 2.264 |
| Previous Close | 2.150 |
| Day's Range | 2.264 - 2.547 |
| 52-Week Range | 0.510 - 4.200 |
| Beta | -0.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 9, 2026 |
About ENGNW
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.
News
enGene Holdings: Key Catalysts Incoming For 2026
enGene Holdings remains on track with a cautiously optimistic 'Buy' rating, supported by promising clinical data and strong financial positioning. ENGN's lead candidate, detalimogene voraplasmid, demo...
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (ENGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the...
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the foll...
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executi...
enGene: Two Major Catalysts On Deck For 2nd Half Of 2026
enGene Holdings (ENGN) maintains a Buy rating, driven by positive preliminary data and two major catalysts expected in 2H 2026. ENGN's detalimogene gene therapy achieved a 62% 6-month complete respons...
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an a...
enGene Reports Full Year 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the...
enGene's Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug...
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Alex Nichols, Ph.D., Chief Strategy and...
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously...
enGene Announces Proposed Public Offering of Common Shares
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an unde...
enGene Holdings: Still A Buy After A Massive Surge
enGene Holdings remains a Buy, driven by promising LEGEND trial data for detalimogene voraplasmid in non-muscle invasive bladder cancer. ENGN's phase 2 LEGEND trial showed a 63% complete response rate...
enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript
enGene Holdings Inc. ( ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC November 11, 2025 8:00 AM EST Company Participants Lauren Hopfer Ronald H. Coope...
EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial
enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data ...
enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a confere...
enGene Named a BioSpace 2026 Best Places to Work Winner
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, today announced that BioSpace has named the ...
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity...
enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc...
enGene Reports Third Quarter 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced its financial results for the thir...
EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
enGene Holdings Inc. (NASDAQ:ENGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Ronald H. Cooper - President, CEO & Director Conference ...
enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced it has achieved its target enrollm...
enGene Announces Board and Leadership Appointments to Support Commercial Readiness
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of t...
FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today announced that the U.S. Food ...